The Pharmacy Times® Infectious Disease Resource Center is a comprehensive resource for clinical news and expert insights on a group of disorders caused by organisms, such as bacteria, viruses, fungi, or parasites.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Practice Pearls from the 2018 Clostridium Difficile Treatment Guidelines
March 6th 2018The IDSA and SHEA have made a recent update to the previously published practice guidelines for CDI. While many of the recommendations remain the same, there are a few key changes that the update has addressed.
Read More
The Sickest Time of the Year: How Brown Bagging Can Bring Clarity
February 25th 2018Community-acquired pneumonia is a common and potentially serious illness, particularly in elderly patients and those with significant comorbidities. Prevention and early identification can have a positive impact on infected individuals, health care economics, and the community.
Read More
Combo Inhibitor Antibiotic Approved to Treat HABP/VABP
February 3rd 2018The US Food and Drug Administration has approved Allergan's supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older.
Read More
Potential Alternative to Carbapenems for Hospital-Acquired Pneumonia?
January 10th 2018Ceftazidime-avibactam, a new antibiotic combination, may be an effective alternative to carbapenem meropenem for the treatment of hospital-acquired pneumonia associated with antimicrobial-resistant Gram-negative pathogens.
Read More